Tumor cells
Tumor cells are the malignant cellular component of a cancerous tumor.
Tumor cells are the malignant cellular component of a cancerous tumor. They arise from genetic and epigenetic alterations that disrupt normal control of proliferation, survival, differentiation, and interaction with the surrounding tumor microenvironment. As a result, tumor cells can acquire properties such as unchecked growth, resistance to apoptosis, immune evasion, invasive behavior, and drug resistance. Their biology is strongly shaped by signals from the tumor microenvironment, including cytokines, metabolic stress, and interactions with stromal cells, immune cells, and extracellular matrix.
In biomedical research, tumor cells are a central therapeutic target for chemotherapy, photochemotherapy, photothermal therapy, immunotherapy, and nanomedicine-based drug delivery. Many recent studies have focused on selectively directing agents to tumor cells, reversing chemoresistance, or inducing immunogenic cell death and cytotoxicity. In these contexts, pathways involving transforming growth factor, reactive oxygen species, glutathione metabolism, and immune checkpoints can influence how tumor cells respond to treatment and how effectively the tumor can be controlled.
Where the papers sit
21 papers from the last 6 months study tumor cells directly · updated from PubMed 10 Nov 2026
Study type 0 clinical trials · 3 human data · 17 preclinical · 1 unclassified
Themes 4 themes · 1 paradigm shift · 1 new direction
-
Tumor Immunity and Vaccines
Tumor immunotherapy is shifting toward deliberate antigen discovery and immune priming alongside checkpoint blockade. In situ, whole-cell and nonself-antigen vaccines are being paired with anti-PD-1 to overcome immunoresistance and increase tumor immunogenicity. AIRE conditioning, plasma-cell antibody profiling and transcriptomic modeling seek more precise tumor epitope and biomarker selection. T-cell antibody-dependent cytotoxicity broadens the strategy beyond direct checkpoint inhibition, but predictive immune markers remain unresolved.
7 papers · 33.3%
-
Ferroptosis-Activating Nanotherapy
Catalytic nanotherapies are moving toward multimodal tumor killing through ferroptosis, reactive oxygen species and immunogenic cell death. Oxygen vacancies, single-atom catalysts and metal-oxo structures are used to generate singlet oxygen or other radicals under ultrasound, light or tumor conditions. Glutathione depletion and iron-dependent oxidative stress recur as ways to intensify therapy. The main opportunity remains coordinating oxygen activation, drug delivery and spatially controlled treatment.
6 papers · 28.6%
-
Stromal Drivers of Chemoresistance
Chemoresistance is being addressed by targeting both tumor cells and their supporting stroma. Cancer-associated fibroblast mitophagy and rewired pyrimidine metabolism emerge as mechanisms of treatment failure, while UBC9 and PI3K may provide prognostic signals in colorectal cancer. Dual-cargo micelles and biomimetic nanomedicines combine chemotherapy with stromal or tumor-cell targeting. Transferrin-directed extracellular vesicles and combination delivery aim to improve doxorubicin and oral chemotherapy responses.
5 papers · 23.8%
-
Iron-Based Tumor Nanotherapy
Iron-centered nanomedicines are being developed to turn tumor chemistry into therapeutic damage. Iron deprivation, Fe3+-responsive delivery and nanozyme-driven chemodynamic therapy target iron dependence or use it to generate reactive species. Combination designs add siRNA-mediated reversal of chemoresistance, photothermal treatment or temozolomide. The shared direction is stimulus-responsive treatment that concentrates oxidative and cytotoxic effects within solid tumors.
3 papers · 14.3%
Tumor cells can be repurposed as immune-priming vaccine material rather than treated only as therapeutic targets
The ionic-liquid whole-tumor-cell vaccine study in B16F10 melanoma and the hyaluronic-acid–OVA peptide study in B16F10 melanoma both treat tumor cells as platforms for initiating immunity rather than merely as cells to be eliminated. The IL-Vax study found that tumor cells undergoing immunogenic death can carry CpG into dendritic cells and generate protective antitumor immunity, while the HA-C-OVA257-264 study found that tumor cells can be induced to display a foreign peptide on MHC class I and become targets for antigen-specific CTLs. Together, these findings replace the target-only view with a model in which tumor cells can be engineered or loaded to function as immune-priming vaccine material 42949972Oct 42826501Oct.
Tumor cells can actively create a thymus-like self-tolerance program
The AIRE-conditioning immunotherapy study of engineered tumor cells found that tumors can mimic the role of AIRE-expressing medullary thymic epithelial cells by establishing a molecular profile of “selfness” that shields them from self-tolerized T cells. Altering AIRE expression reset this profile and exposed both modified and parental tumor cells to immune attack. This gives tumor cells an active immune-educating and tolerance-shaping role not represented by the other abstracts, changing the therapeutic objective from targeting tumor antigens alone to disrupting tumor-imposed immunologic selfness 42644627Aug.
Papers
The 21 papers from the last 6 months that study tumor cells directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Tumor Immunity and Vaccines (7)
- T cell-mediated antibody-dependent cellular cytotoxicity provides a therapeutic approach for solid cancers. JCI insight · 9 Nov 2026 PMID 43001588
- Ionic liquid-mediated cellular loading for whole tumor cell vaccines. Proceedings of the National Academy of Sciences of the United States of America · 28 Oct 2026 PMID 42949972
- Enhancing Tumor Immunogenicity through Hyaluronic Acid-Mediated Delivery of Nonself Antigenic Peptides. ACS applied bio materials · 2 Oct 2026 PMID 42826501
- Integrating tumor-immune mechanistic modeling with transcriptomics reveals pattern-driven prognostic biomarkers in tumors. Proceedings of the National Academy of Sciences of the United States of America · 10 Sept 2026 PMID 42721081
- Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome. Cancer immunology research · 26 Aug 2026 PMID 42644627
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies. Cancer cell · 27 Jul 2026 PMID 42508408
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
Ferroptosis-Activating Nanotherapy (6)
- Endowing Centrosymmetric Oxides with Effective Piezoelectricity via Oxygen Vacancy Engineering and Single-Atom Anchoring for Multicatalytic Sono-Immunotherapy. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619089
- Tailoring Crystallization Modulators for the Facile Synthesis of One-Dimensional Covalent Organic Frameworks to Boost Ultrasound-Triggered Pyroptosis and Immunotherapy. Angewandte Chemie (International ed. in English) · 19 Aug 2026 PMID 42615286
- Biomimetic Synthesis of Multinuclear Metal-Oxo Bridges Under Mild Aqueous Conditions for Catalytic Cancer Therapy. Angewandte Chemie (International ed. in English) · 6 Aug 2026 PMID 42559927
- Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
- Photoelectric Therapy Needle-Combined ICG-Cu(II)-AIBI Infinite Coordination Polymer Nanoparticles for Free Radical Spatiotemporal-Matched Photodynamic-Thermodynamic Tumor Synergistic Therapy. ACS applied materials & interfaces · 15 Jun 2026 PMID 42295973
- Engineered maleoyl-chitosan grafted with oligopeptides nanogels with dual-mode mobility toward melanoma therapy. International journal of biological macromolecules · 2 Jun 2026 PMID 42229647
Stromal Drivers of Chemoresistance (5)
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- UBC9 and PI3K Expression in Colorectal Cancer: Possible Prognostic Role. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 29 Jul 2026 PMID 42522541
- In Situ Transferrin-Mediated Sandwich-like Targeting with Engineered Ginger-Derived Extracellular Vesicles for Precision Oral Chemotherapy of Colorectal Cancer. ACS nano · 22 Jul 2026 PMID 42486784
- Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer. ACS applied bio materials · 20 Jul 2026 PMID 42474418
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
Iron-Based Tumor Nanotherapy (3)
- Iron-Deprivation Liposomes for Cancer Therapy. Angewandte Chemie (International ed. in English) · 9 Sept 2026 PMID 42711711
- Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal-temozolomide therapy for glioblastoma. Acta biomaterialia · 18 Jun 2026 PMID 42315000
- In Situ Electroactive Bacteria-Activated Nanozyme for Amplifying Chemodynamic Therapy of Solid Tumors. Nano letters · 22 May 2026 PMID 42170851
By study type
Human data, design not indexed (3)
- Integrating tumor-immune mechanistic modeling with transcriptomics reveals pattern-driven prognostic biomarkers in tumors. Proceedings of the National Academy of Sciences of the United States of America · 10 Sept 2026 PMID 42721081
- Tailoring Crystallization Modulators for the Facile Synthesis of One-Dimensional Covalent Organic Frameworks to Boost Ultrasound-Triggered Pyroptosis and Immunotherapy. Angewandte Chemie (International ed. in English) · 19 Aug 2026 PMID 42615286
- UBC9 and PI3K Expression in Colorectal Cancer: Possible Prognostic Role. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 29 Jul 2026 PMID 42522541
Preclinical: animal, cell and lab studies (17)
- T cell-mediated antibody-dependent cellular cytotoxicity provides a therapeutic approach for solid cancers. JCI insight · 9 Nov 2026 PMID 43001588
- Ionic liquid-mediated cellular loading for whole tumor cell vaccines. Proceedings of the National Academy of Sciences of the United States of America · 28 Oct 2026 PMID 42949972
- Enhancing Tumor Immunogenicity through Hyaluronic Acid-Mediated Delivery of Nonself Antigenic Peptides. ACS applied bio materials · 2 Oct 2026 PMID 42826501
- Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome. Cancer immunology research · 26 Aug 2026 PMID 42644627
- Endowing Centrosymmetric Oxides with Effective Piezoelectricity via Oxygen Vacancy Engineering and Single-Atom Anchoring for Multicatalytic Sono-Immunotherapy. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619089
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- Biomimetic Synthesis of Multinuclear Metal-Oxo Bridges Under Mild Aqueous Conditions for Catalytic Cancer Therapy. Angewandte Chemie (International ed. in English) · 6 Aug 2026 PMID 42559927
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies. Cancer cell · 27 Jul 2026 PMID 42508408
- In Situ Transferrin-Mediated Sandwich-like Targeting with Engineered Ginger-Derived Extracellular Vesicles for Precision Oral Chemotherapy of Colorectal Cancer. ACS nano · 22 Jul 2026 PMID 42486784
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
- Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer. ACS applied bio materials · 20 Jul 2026 PMID 42474418
- Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
- Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal-temozolomide therapy for glioblastoma. Acta biomaterialia · 18 Jun 2026 PMID 42315000
- Photoelectric Therapy Needle-Combined ICG-Cu(II)-AIBI Infinite Coordination Polymer Nanoparticles for Free Radical Spatiotemporal-Matched Photodynamic-Thermodynamic Tumor Synergistic Therapy. ACS applied materials & interfaces · 15 Jun 2026 PMID 42295973
- Engineered maleoyl-chitosan grafted with oligopeptides nanogels with dual-mode mobility toward melanoma therapy. International journal of biological macromolecules · 2 Jun 2026 PMID 42229647
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
- In Situ Electroactive Bacteria-Activated Nanozyme for Amplifying Chemodynamic Therapy of Solid Tumors. Nano letters · 22 May 2026 PMID 42170851
Unclassified: not yet indexed with MeSH (1)
- Iron-Deprivation Liposomes for Cancer Therapy. Angewandte Chemie (International ed. in English) · 9 Sept 2026 PMID 42711711
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-08-19. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.